In Q3 2025, Kenvue Inc. reported quarterly revenue of $3.8 billion and net income of $398 million. This represents a decline in revenue growth by -1.95% compared to the previous quarter, but an improvement in profit growth by 0.99%. Despite this, Kenvue's operating margin remains strong at 17.59%, outperforming the sector average of 15.7%. The company's net margin stands at 9.55%.
Looking deeper into the trends, Kenvue's 3-year revenue CAGR is only 1.11% with a negative 3-year profit CAGR of -0.66%. These numbers indicate that the company has been struggling to grow its revenue and profitability over time. Additionally, Kenvue has not experienced any consecutive growth quarters, which could be a concern for investors. However, the company's margin improvement of 0.84% is a positive sign, indicating that they are taking steps to improve their financial performance.
From a news perspective, recent articles suggest a positive outlook for Kenvue based on Johnson & Johnson's solid Q4 results and improved profitability. The company also maintained its 'Dividend King' status with a 2.3-2.5% yield and strong balance sheet. Furthermore, Kenvue experienced 9.1% revenue growth to $24.56 billion in the same quarter, driven by strong oncology and immunology demand.
Despite these strengths, potential concerns for Kenvue include its declining revenue growth and profitability over time. Additionally, the company has not experienced any consecutive growth quarters, which could be a concern for investors. Overall, while Kenvue's financial performance may be challenging, its strong balance sheet and positive outlook from recent news suggest that it is worth considering as an investment opportunity. Moving forward, investors should closely monitor the company's progress in improving its revenue and profit growth to better understand its long-term prospects.